

ChemoCentryx, Inc. Investor Relations Department 850 Maude Avenue Mountain View, CA 94043 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: CCXI	
Last Trade:	10.09
Trade Time:	4:00 PM ET Jul 25, 2017
Change:	-0.16 🗣 (-1.561%)
Day Range	9.91 - 10.33
52-Week Range	3.95 - 10.68
Volume	149,204

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ChemoCentrvx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases. inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... (more)

Stock Performance



Press Releases [View all]

Jun 6, 2017

Oral Presentations at ERA-EDTA Congress
Highlight Fourth Potential Indication for
Avacopan and Potential for CCR2 Inhibition
in Focal Segmental Glomerulosclerosis
(FSGS)

May 24, 2017

<u>ChemoCentryx to Present at Two Upcoming</u> <u>Investor Conferences</u>

May 23, 2017

ChemoCentryx Granted EU Orphan Drug

Designation for Avacopan in the Treatment
of Debilitating Kidney Disease C3

Glomerulopathy (C3G)

May 10, 2017

<u>ChemoCentryx Reports First Quarter 2017</u> Financial Results

Apr 27, 2017

ChemoCentryx to Hold First Quarter 2017
Financial Results Conference Call on
Wednesday, May 10, 2017

Financials [View all]

Mar 14, 2017 Annual Report (10-K)

Apr 10, 2017
Proxy Statement (DEF 14A)

May 10, 2017 Quarterly Report (10-Q)

Nov 8, 2016
Quarterly Report (10-Q)

Aug 9, 2016
Quarterly Report (10-Q)